Journal article
Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial
Abstract
BackgroundVenous thromboembolism (VTE) is a common complication of critical illness with important clinical consequences. The Prophylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) is a multicenter, blinded, randomized controlled trial comparing the effectiveness of the two most common pharmocoprevention strategies, unfractionated heparin (UFH) and low molecular weight heparin (LMWH) dalteparin, in medical-surgical patients in the …
Authors
Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B
Journal
Trials, Vol. 15, No. 1,
Publisher
Springer Nature
Publication Date
12 2014
DOI
10.1186/1745-6215-15-502
ISSN
1468-6708
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AnticoagulantsAustraliaBrazilClinical ProtocolsCost SavingsCost-Benefit AnalysisCritical CareDalteparinDrug CostsFibrinolytic AgentsHeparinHospital CostsHumansModels, EconomicNorth AmericaProspective StudiesQuality-Adjusted Life YearsResearch DesignSaudi ArabiaTime FactorsTreatment OutcomeVenous Thromboembolism